AVID Medical Recalls Organ Recovery Kit Due to Unsuitability
AVID Medical recalled 132 units of its Organ Recovery Kit on November 11, 2025. The devices are not suitable for organ transplant, posing a high risk to patients. Healthcare providers and patients should stop using the device immediately and follow recall instructions.
Quick Facts at a Glance
Recall Date
November 11, 2025
Hazard Level
HIGH
Brand
AVID Medical
Category
Health & Personal Care
Sold At
Unknown
Geographic Scope
1 states
At-Risk Groups
GENERAL
Hazard Information
Devices are not suitable for organ transplant.
What You Should Do
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact AVID Medical, Inc. or your healthcare provider for instructions. Notification method: E-Mail
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
No spamUnsubscribe anytime
Product Details
The recalled product is the Organ Recovery Kit, Kit Code: LLOG1000-15. It was distributed nationwide in Florida, Georgia, and Puerto Rico. The affected lot numbers are 1632138 and 1648393.
The Hazard
The Organ Recovery Kit is unsuitable for organ transplant. This defect poses a high risk, potentially affecting patient safety during medical procedures.
Reported Incidents
No specific incidents of injury or death have been reported at this time. The recall is classified as Class I due to the high hazard level.
What to Do
Stop using the Organ Recovery Kit immediately. Contact AVID Medical or your healthcare provider for instructions on returning the product.
Contact Information
For further information, contact AVID Medical, Inc. via email. Additional details are available at the FDA recall notice link.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.